Format

Send to

Choose Destination
Curr Opin Mol Ther. 2001 Aug;3(4):418-24.

Technology evaluation: IMC-1C11, ImClone Systems.

Author information

1
dshunt@easynet.co.uk

Abstract

ImClone is developing IMC-IC11, an anti-angiogenesis chimeric monoclonal antibody specific vascular endothelial growth factor receptor 2 (VEGFR-2, also known Flk-1 in mice), for the potential treatment of cancer [156625]; it in phase I trials for the treatment of colorectal carcinoma [379143]. The related antibody DC-101 provided proof-of-principle that an anti-VEGF receptor antibody could strongly inhibit tumor growth and even cause tumor regression with the glioblastoma tumor cell line, GBM18 [388236]. In May 1998, the company was granted US-05747651 by the USPTO, covering antibodies against the extracellular portion of the FLK-1/KDR receptor [284054].

PMID:
11525567
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center